Recombinant erythropoietin down-regulates IL-6 and CXCR4 genes in TNF-α-treated primary cultures of human microvascular endothelial cells: Implications for multiple sclerosis

Jagannadha R. Avasarala, Sastry S. Konduru

Research output: Contribution to journalArticle

24 Citations (Scopus)


In multiple sclerosis (MS), disruption of the blood-brain barrier might lead to new gadolinium-enhanced lesion formation in the brain and cause acute relapses. Current therapeutic options for acute relapses in MS are limited. The effect of recombinant erythropoietin (rEPO) on cytokine gene expression in TNF-α-treated human brain microvascular endothelial cells was studied. The cells were controls (untreated), exposed for either 6 or 24 h to TNF-α or TNF-α/rEPO. Of the 96 genes studied, interleukin-6 (IL-6), IL-1β, CXCR4, and IL-1α genes were down-regulated when treated with TNF-α/rEPO for 6 h as compared with TNF-α alone. At 24 h, IL-6 and CXCR4 gene expression was 4.24 and 2.98, respectively. Quantitative RT-PCR analysis showed down-regulation by 3.86 and 1.9 for IL-6 and CXCR4 genes, respectively. Our findings suggest that further studies are warranted to evaluate the use of EPO in minimizing acute relapses in MS.

Original languageEnglish
Pages (from-to)183-189
Number of pages7
JournalJournal of Molecular Neuroscience
Issue number2
Publication statusPublished - 1 Feb 2005



  • Blood-brain barrier
  • Gene profiling
  • IL-6 and CXCR4 genes
  • Multiple sclerosis
  • Recombinant erythropoietin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this